Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study
Anton Hagenbeek,
Hans Mooij,
Josée Zijlstra,
Pieternella Lugtenburg,
Gustaaf van Imhoff,
Marcel Nijland,
Sanne Tonino,
Martin Hutchings,
Marjolein Spiering,
Roberto Liu,
Harm van Tinteren,
Marie José Kersten
Affiliations
Anton Hagenbeek
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands
Hans Mooij
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands
Josée Zijlstra
Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands
Pieternella Lugtenburg
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Gustaaf van Imhoff
Department of Hematology, University Medical Center Groningen, the Netherlands
Marcel Nijland
Department of Hematology, University Medical Center Groningen, the Netherlands
Sanne Tonino
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands;Lymphoma and Myeloma Center Amsterdam (LYMMCARE), the Netherlands
Martin Hutchings
Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark
Marjolein Spiering
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands
Roberto Liu
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands
Harm van Tinteren
Biometric Department, NKI-AVL, Amsterdam, the Netherlands
Marie José Kersten
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands;Lymphoma and Myeloma Center Amsterdam (LYMMCARE), the Netherlands
